Full Press Release Details
Oncolytics Biotech Inc. Announces Phase 3 Update
CALGARY, AB, --- October 1,
2009 - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc.
("Oncolytics") (TSX:ONC, NASDAQ:ONCY), will host a conference call and webcast
on Friday, October 2, 2009 at
6:30 a.m. MT (8:30 a.m. ET) to update investors on the Company's Phase 3
program for REOLYSIN .
the conference call by telephone, dial 1-416-644-3426 or 1-800-732-1073. A live
audio webcast will also be available at the following link: http://www.newswire.ca/en/webcast/viewEvent.cgi?eventID=2828320 or through the Company's
website at www.oncolyticsbiotech.com. Please
connect at least 15 minutes prior to the webcast to ensure adequate time for any
software download that may be needed. A replay of the webcast will be available
and will also be available by telephone through October 9, 2009. To access the
telephone replay, dial 1-416-640-1917 or 1-877-289-8525 and enter reservation
Oncolytics Biotech Inc.
is a Calgary-based biotechnology company focused on the development of oncolytic
viruses as potential cancer therapeutics. Oncolytics' clinical
program includes a variety of Phase I/II and Phase II human trials using
REOLYSIN, its proprietary formulation of the human reovirus, alone and in
combination with radiation or chemotherapy. For further information
about Oncolytics, please visit www.oncolyticsbiotech.com
press release contains forward-looking statements, within the meaning of Section
21E of the Securities Exchange Act of 1934, as amended. Forward-looking
statements, including the Company's expectations as to the Phase 3 program for
REOLYSIN, and the potential of REOLYSIN as a cancer therapeutic, involve known
and unknown risks and uncertainties, which could cause the Company's actual
results to differ materially from those in the forward-looking statements. Such
risks and uncertainties include, among others, the availability of funds and
resources to pursue research and development projects, the efficacy of REOLYSIN
as a cancer treatment, the tolerability of REOLYSIN outside a controlled test,
the success and timely completion of clinical studies and trials, the Company's
ability to successfully commercialize REOLYSIN, uncertainties related to the
research and development of pharmaceuticals and uncertainties related to the
regulatory process. Investors should consult the Company's quarterly and annual
filings with the Canadian and U.S. securities commissions for additional
information on risks and uncertainties relating to the forward looking
statements. Investors are cautioned against placing undue reliance on
forward-looking statements. The Company does not undertake to update these
forward-looking statements.
FURTHER INFORMATION PLEASE CONTACT: